These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20547658)

  • 21. Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study.
    Westhovens R; Ravelingien I; Vandevyvere K; Pansar I; Purcaru O; Kumke T; Gyselbrecht L
    Acta Clin Belg; 2019 Oct; 74(5):342-350. PubMed ID: 30160189
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Certolizumab pegol for the treatment of rheumatoid arthritis.
    Horton S; Walsh C; Emery P
    Expert Opin Biol Ther; 2012 Feb; 12(2):235-49. PubMed ID: 22165979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.
    Bessette L; Haraoui B; Chow A; Fortin I; Dixit S; Khraishi M; Haaland D; Elmoufti S; Staelens F; Bogatyreva I; Syrotuik J; Shaikh S
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19831151. PubMed ID: 30858896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
    Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
    Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
    J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).
    Osterhaus JT; Purcaru O; Richard L
    Arthritis Res Ther; 2009; 11(3):R73. PubMed ID: 19457255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.
    Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H
    Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
    Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
    Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
    Pope J; Bingham CO; Fleischmann RM; Dougados M; Massarotti EM; Wollenhaupt J; Duncan B; Coteur G; Weinblatt ME
    Arthritis Res Ther; 2015 Nov; 17():343. PubMed ID: 26614481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
    Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
    Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure.
    Blanco FJ; Rubio-Romero E; Sanmartí R; Díaz-Torné C; Talavera P; Dunkel J; Naredo E;
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):345-352. PubMed ID: 30236749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V; Tundia N; Wells A; Buch MH; Radominski SC; Camp HS; Friedman A; Suboticki JL; Dunlap K; Goldschmidt D; Bergman M
    Rheumatology (Oxford); 2021 Jul; 60(7):3209-3221. PubMed ID: 33313898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Certolizumab pegol in rheumatoid arthritis: current update.
    Fechtenbaum M; Md Yusof MY; Emery P
    Expert Opin Biol Ther; 2014 Jun; 14(6):841-50. PubMed ID: 24654999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.
    Kumar N; Naz S; Quinn M; Ryan J; Kumke T; Sheeran T
    Adv Ther; 2018 Sep; 35(9):1426-1437. PubMed ID: 30076523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
    Feagan BG; Coteur G; Tan S; Keininger DL; Schreiber S
    Am J Gastroenterol; 2009 Aug; 104(8):1976-83. PubMed ID: 19471252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.